Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | When is the optimal time to use PARP inhibitors in prostate cancer patients?

Joaquin Mateo, MD, from the Institute of Cancer Research and The Royal Marsden, London, UK speaks to us about the current state of our understanding on the optimal time to administer PARP inhibitors in prostate cancer patients, and tells us why healthcare professionals may be encouraged to utilize them as early as possible. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.